Aoxing Pharmaceutical Company, Inc. announced earnings results for the second quarter and six months ended December 31, 2012. For the quarter, the company reported revenue of $3,314,768, representing a 56% increase over the revenues realized in the same period last year. Loss from operations was $2,352,385 compared with $150,860 a year ago. Net loss was $3,135,661. The increase in revenue was mainly attributable to the increase in sales of main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market.

For the six months, the company reported revenue of $5,919,531, representing a 62% increase over the revenues realized in the same period last year. Loss from operations was $2,264,906 compared with $646,817 a year ago. Net loss was $3,584,176.